FindTrial
Sign In

Anti-Mullerian Hormone and the Success of Intrauterine Insemination in Women with Unexplained Infertility

The Role of Anti Mullerian Hormone as a Predictor of Intrauterine Insemination Outcome in Women with Unexplained Infertility A Prospective Cohort Study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/114151
Enrollment
124
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Control Intervention1: nil: nil

Sponsors

Government Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Unexplained infertility at least a single fallopian tube patent, normal semen parameters mild abnormality, regular cycles. Eligible for IUI Willing to participate.

Exclusion criteria

Exclusion criteria: Women with uterine pathology like myoma, endometriosis and uterine anomalies. History of ovarian surgery or chemotherapy. Known PCOS, tubal pathology or male factor infertility. Elevated FSH or abnormal thyroid or prolactin levels. History of cervical surgeries, cervical amputation. Co existing chronic diseases like diabetes mellitus, hypertension, etc.

Design outcomes

Primary

MeasureTime frame
Urine pregnancy test Presence of gestational sac on transvaginal ultrasound Number of mature follicles on the day of trigger Assessment for foetal viability in confirmed clinical pregnancy via TVSTimepoint: 3 weeks, 8 weeks—

Secondary

MeasureTime frame
NilTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Tanya Verma

Government Institute of Medical Sciences

guptadrarchana@gmail.com9838977665

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026